A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease

[1]  K. Niendorf,et al.  What’s the Harm? Genetic Counselor Perceptions of Adverse Effects of Genetics Service Provision by Non-Genetics Professionals , 2014, Journal of Genetic Counseling.

[2]  R. Green,et al.  Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease , 2012, Genetics in Medicine.

[3]  Susan E. Hahn,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors: Erratum , 2011, Genetics in Medicine.

[4]  Richard Mayeux,et al.  Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors , 2011, Genetics in Medicine.

[5]  R. Green,et al.  Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk , 2011, Genetics in Medicine.

[6]  H. Arrighi,et al.  Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis , 2010, Dementia and Geriatric Cognitive Disorders.

[7]  K. Brierley,et al.  Errors in delivery of cancer genetics services: implications for practice. , 2010, Connecticut medicine.

[8]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[9]  R. Green,et al.  A New Scale Measuring Psychologic Impact of Genetic Susceptibility Testing for Alzheimer Disease , 2009, Alzheimer disease and associated disorders.

[10]  Katherine Payne,et al.  Outcome measurement in clinical genetics services: a systematic review of validated measures. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  A. Edwards,et al.  Interventions to improve risk communication in clinical genetics: systematic review. , 2008, Patient education and counseling.

[12]  Robert Cook-Deegan,et al.  Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience , 2008, Genetics in Medicine.

[13]  S. Steinberg,et al.  Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling , 2007, Genetics in Medicine.

[14]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[15]  Robert C Green,et al.  Genetic Risk Assessment for Adult Children of People With Alzheimer’s Disease: The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study , 2005, Journal of geriatric psychiatry and neurology.

[16]  S. Steinberg,et al.  Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Michael J Green,et al.  Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. , 2004, JAMA.

[18]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[19]  R. Green,et al.  Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial , 2004, Genetics in Medicine.

[20]  R. Green,et al.  Reasons for Seeking Genetic Susceptibility Testing Among First‐Degree Relatives of People With Alzheimer Disease , 2003, Alzheimer disease and associated disorders.

[21]  J. Schafer,et al.  A comparison of inclusive and restrictive strategies in modern missing data procedures. , 2001, Psychological methods.

[22]  S. Snapinn.  Noninferiority trials , 2000, Current controlled trials in cardiovascular medicine.

[23]  K. Marder,et al.  The APOE- (cid:101) 4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 2001 .

[24]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[25]  J. Ramsay,et al.  Examining scale discriminability in the BDI and CES-D as a function of depressive severity. , 1995 .

[26]  L. Wilkins.  Guidelines for the molecular genetics predictive test in Huntington's disease , 1994, Neurology.

[27]  International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. , 1994, Journal of medical genetics.

[28]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.

[29]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[30]  M. Horowitz,et al.  Impact of Event Scale: A Measure of Subjective Stress , 1979, Psychosomatic medicine.

[31]  Colleen Reding.  University of Michigan , 1868, Radiocarbon.

[32]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[33]  A. Falek,et al.  Guidelines for the molecular genetics predictive test in Huntington's disease , 1994 .

[34]  浜田賀代子,et al.  老年期痴呆患者のスクリーニングにおけるThe modified mini-mental state (3MS) examination日本語版の有用性 , 1992 .

[35]  L. Radloff.  The CES-D Scale: A Self-Report Depression Scale for Research in the General Population — Source link , 2022 .